Company Description

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Achieve Life Sciences, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Andrew Goldberg

Contact Details

Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States
Phone	604 210 2217
Website	achievelifesciences.com

Stock Details

Ticker Symbol	ACHV
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0000949858
CUSIP Number	004468203
ISIN Number	US0044685008
Employer ID	95-4343413
SIC Code	2835

Key Executives

Name	Position
Dr. Andrew D. Goldberg M.D.	Chief Executive Officer and Director
Mark K. Oki CPA	Chief Financial Officer
Craig Donnelly	Chief Operations Officer
Jerry Wan	Vice President of Finance and Principal Accounting Officer
Erik Atkisson	Chief Legal Officer
Jaime Xinos	Chief Commercial Officer
Dr. Mark L. Rubinstein M.D.	Chief Medical Officer
Nicole P. Jones	Vice President of Strategic Communications and Stakeholder Relations

Latest SEC Filings

Date	Type	Title
Apr 30, 2026	10-K/A	[Amend] Annual report
Apr 27, 2026	SCHEDULE 13D	Filing
Apr 24, 2026	SCHEDULE 13G	Filing
Apr 24, 2026	SCHEDULE 13D	Filing
Apr 24, 2026	SCHEDULE 13G	Filing
Apr 24, 2026	SCHEDULE 13G	Filing
Apr 16, 2026	8-K	Current Report
Apr 16, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 24, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 24, 2026	10-K	Annual Report

View All SEC Filings